Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Bendell JC, et al. Clin Cancer Res. 2014 Jan 15;20(2):480-9. doi: 10.1158/1078-0432.CCR-13-1840. Epub 2013 Oct 30. Clin Cancer Res. 2014. PMID: 24173543 Clinical Trial.
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. Jimeno A, et al. Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20. Cancer. 2016. PMID: 27648727 Free PMC article. Clinical Trial.
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB. Voss MH, et al. Clin Cancer Res. 2017 Jul 15;23(14):3557-3565. doi: 10.1158/1078-0432.CCR-16-2395. Epub 2016 Dec 28. Clin Cancer Res. 2017. PMID: 28031424 Clinical Trial.
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
Meher N, Ashley GW, Bobba KN, Wadhwa A, Bidkar AP, Dasari C, Mu C, Sankaranarayanan RA, Serrano JAC, Raveendran A, Bulkley DP, Aggarwal R, Greenland NY, Oskowitz A, Wilson DM, Seo Y, Santi DV, VanBrocklin HF, Flavell RR. Meher N, et al. Among authors: wilson dm. Adv Healthc Mater. 2024 May 3:e2304618. doi: 10.1002/adhm.202304618. Online ahead of print. Adv Healthc Mater. 2024. PMID: 38700450
Genomic stress and impaired DNA repair in Alzheimer disease.
Neven J, Issayama LK, Dewachter I, Wilson DM 3rd. Neven J, et al. Among authors: wilson dm 3rd. DNA Repair (Amst). 2024 Apr 11;139:103678. doi: 10.1016/j.dnarep.2024.103678. Online ahead of print. DNA Repair (Amst). 2024. PMID: 38669748
995 results